-
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
04 Dec 2025 12:00 GMT
… unique multi-arm design in treatment-resistant cancers
REHOVOT, … GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) … upcoming European Society of Medical Oncology Immuno-Oncology ( … and in combination with cetuximab, in which NT219 …
-
<![CDATA[Rx Road Map: Adagrasib With Cetuximab for KRAS G12C-Mutated mCRC]]>
03 Dec 2025 19:41 GMT
… /2 KRYSTAL-1 trial (NCT03785249), upon which the … equipment and medications are readily available before initiating treatment. Premedicate … fda.gov/drugs/;resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab …
-
Colorectal Cancer Drugs Market to hit US$ 19.96 billion by 2033, (CAGR of 5.2%)
02 Dec 2025 07:21 GMT
… pipeline of novel drugs under clinical trials focusing on better … market.Strong presence of pharmaceutical companies and advanced … combination with cetuximab and mFOLFOX6, for the treatment of … between pharma and biotech companies to develop combination …
-
Anticancer Drugs Market Set to Expand at 9.14% CAGR, Reaching USD 401.32 Billion by 2034
21 Nov 2025 13:00 GMT
… drugs, making treatment more accessible. Focus on personalised medicine: … and emerging economies. Pharmaceutical companies are also … therapy
FDA approved
NCT05257408
Encora + Cetuximab
Colorectal … . Clinical Trials & Approval Clinical trials start with …
-
<![CDATA[Illuminating the Sequence of Third-Line Therapies in Metastatic CRC]]>
18 Dec 2025 05:23 GMT
… discussion on the evolving treatment landscape for mCRC. Parseghian … of Gastrointestinal Medical Oncology, Division of Cancer Medicine at … findings from several trials to illustrate how … or adagrasib [Krazati], and cetuximab or panitumumab [Vectibix]. There …
-
Cancer Gene Therapy Market Size to hit $19.97 Billion by 2033 | Key Drivers, Trends, Precision Oncology & FDA
30 Oct 2025 07:32 GMT
… FDA approved a combination therapy of adagrasib and cetuximab … maturing regulatory landscape. Pharmaceutical giants such as Novartis … , and active clinical trials.
Europe (34.5% … science, and biotechnology to redefine oncology treatment. While challenges …
-
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
29 Oct 2025 11:33 GMT
… immune response. About Purple Biotech Purple Biotech Ltd. (NASDAQ… 2 study for the treatment of pancreatic ductal adenocarcinoma … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents’ Delivery Against Lung Cancer: A Review
24 Oct 2025 14:10 GMT
… of NSCLC cells.71
Medication Delivery Utilizing Active … in cancer diagnosis and treatment. Pharmaceutics. 2023;15(3):1025 … chitosan for cancer nano drug delivery. Biotechnol Adv. 2023;67 … Billa N, Roberts CJ. Cetuximab-conjugated chitosan-pectinate (modified) …
-
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects
24 Oct 2025 08:14 GMT
… the drug’s potential for pancreatic and colorectal cancer treatment.
Retail … Medical Officer John Hayslip said the company is encouraged by the drug … ongoing combination trial with cetuximab addresses “a significant unmet need for treatments specifically …
-
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
24 Oct 2025 06:00 GMT
… biotechnology company pioneering physics-based approaches to expand treatment … States Food and Drug Administration granted regulatory Fast … with or without cetuximab, for the treatment of patients with … (NBTXR3) with Janssen Pharmaceutica NV, a Johnson …
About
© 1995-2025